Rigel Pharmaceuticals, Inc. (RIGL)
RIGL Stock Price Chart
Explore Rigel Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze RIGL price movements and trends.
RIGL Company Profile
Discover essential business fundamentals and corporate details for Rigel Pharmaceuticals, Inc. (RIGL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
29 Nov 2000
Employees
162.00
Website
https://www.rigel.comCEO
Raul R. Rodriguez
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase III clinical trial for the treatment of hospitalized COVID-19 patients; and phase III clinical trial for the treatment of COVID-19. In addition, the company is developing R289, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
RIGL Financial Timeline
Browse a chronological timeline of Rigel Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is $0.73, while revenue estimate is $61.88M.
Earnings released on 5 Aug 2025
EPS came in at $3.28 surpassing the estimated $1.97 by +66.50%, while revenue for the quarter reached $101.69M , beating expectations by +63.20%.
Earnings released on 6 May 2025
EPS came in at $0.63 surpassing the estimated $0.14 by +350.00%, while revenue for the quarter reached $53.33M , beating expectations by +10.38%.
Earnings released on 4 Mar 2025
EPS came in at $0.80 surpassing the estimated $0.30 by +166.67%, while revenue for the quarter reached $57.60M , beating expectations by +0.01%.
Earnings released on 7 Nov 2024
EPS came in at $0.70 surpassing the estimated $0.06 by +1.07K%, while revenue for the quarter reached $55.31M , beating expectations by +16.63%.
Earnings released on 6 Aug 2024
EPS came in at -$0.06 surpassing the estimated -$0.37 by +83.78%, while revenue for the quarter reached $36.84M , beating expectations by +10.24%.
Stock split effective on 27 Jun 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 7 May 2024
EPS came in at -$0.50 falling short of the estimated -$0.30 by -66.67%, while revenue for the quarter reached $29.53M , missing expectations by -5.58%.
Earnings released on 5 Mar 2024
EPS came in at $0.04 surpassing the estimated $0.02 by +100.00%, while revenue for the quarter reached $35.79M , beating expectations by +4.96%.
Earnings released on 7 Nov 2023
EPS came in at -$0.30 surpassing the estimated -$0.70 by +57.14%, while revenue for the quarter reached $28.13M , missing expectations by -5.53%.
Earnings released on 1 Aug 2023
EPS came in at -$0.40 surpassing the estimated -$0.80 by +50.00%, while revenue for the quarter reached $26.89M , beating expectations by +4.61%.
Earnings released on 2 May 2023
EPS came in at -$0.80 surpassing the estimated -$0.90 by +11.11%, while revenue for the quarter reached $26.07M , beating expectations by +8.31%.
Earnings released on 7 Mar 2023
EPS came in at $0.10 surpassing the estimated -$0.70 by +114.29%, while revenue for the quarter reached $51.28M , beating expectations by +40.39%.
Earnings released on 3 Nov 2022
EPS came in at -$1.10 surpassing the estimated -$1.30 by +15.38%, while revenue for the quarter reached $22.41M , missing expectations by -0.88%.
Earnings released on 2 Aug 2022
EPS came in at -$0.80 surpassing the estimated -$1.20 by +33.33%, while revenue for the quarter reached $29.82M , beating expectations by +26.06%.
Earnings released on 3 May 2022
EPS came in at -$1.60 falling short of the estimated -$1.20 by -33.33%, while revenue for the quarter reached $16.74M , missing expectations by -4.79%.
Earnings released on 1 Mar 2022
EPS came in at -$1.30 matching the estimated -$1.30, while revenue for the quarter reached $20.41M , missing expectations by -6.80%.
Earnings released on 2 Nov 2021
EPS came in at -$1.20 falling short of the estimated -$1.00 by -20.00%, while revenue for the quarter reached $21.54M , missing expectations by -8.56%.
Earnings released on 3 Aug 2021
EPS came in at -$0.80 surpassing the estimated -$1.10 by +27.27%, while revenue for the quarter reached $26.27M , beating expectations by +28.94%.
Earnings released on 5 May 2021
EPS came in at $2.20 surpassing the estimated $0.10 by +2.10K%, while revenue for the quarter reached $81.02M , missing expectations by -94.44%.
Earnings released on 2 Mar 2021
EPS came in at -$1.10 falling short of the estimated -$1.00 by -10.00%, while revenue for the quarter reached $18.45M .
Earnings released on 5 Nov 2020
EPS came in at -$0.80 surpassing the estimated -$1.20 by +33.33%, while revenue for the quarter reached $18.39M , missing expectations by -33.33%.
RIGL Stock Performance
Access detailed RIGL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.